Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study

Table 1 Baseline characteristics of enrolled patients (mean ± SD)

	PR group (n = 15)	PK group (n = 16)	PRK group (n = 14)	P-value
Age (yr)	45 ± 12	48 ± 12	42 ± 10	NS
Sex (M/F)	9/6	9/7	9/5	NS
HCV-RNA × 103 IU/mL	429 ± 578	1261 ± 1073	1555 ± 1322	0.01
HCV-RNA > 700 × 103 IU/mL (%)	4 (27)	8 (50)	10 (71)	0.02
ALT (U/L)	82 ± 45	85 ± 33	87 ± 49	NS
Median total HAI1 (range)	8 (3-14)	10 (6-13)	8 (3-10)	NS
Median grading (range)	7 (2-11)	9 (5-10)	7 (3-9)	NS
Median fibrosis (range)	1 (1-3)	1 (1-3)	1 (0-3)	NS

¹HAI: Histological activity index according to Knodell et al[22]. PR: PEG-IFNα2a plus ribavirin; PK: PEG-IFNα2a plus ketoprofen; PRK: PEG-IFNα2a plus ribavirin and ketoprofen; M: Male; F: Female; HCV: Hepatitis C virus; ALT: Alanine aminotransferase; NS: Not significant.